Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)

Key Highlights

• Likoper/Shutterstock. com On December 17, management shared updates on the Phase 2 clinical study on KPL-387 monotherapy.
• The aim is to make a safe transition from existing therapies towards KPL-387 for patients with recurrent pericarditis.
• The study will be based on a preliminary 16-week period followed by a long-term extension phase.
• The follow up phase will span across 24 months, where patients would continue to use the drug as needed.
• As per management, successful outcomes of the study could lead to an increase in pipeline value for Kiniksa Pharmaceuticals International (NASDAQ:KNSA).